Anktiva clinical trials
Anktiva is named as an intervention in 14 current clinical trials in our USA, Mexico, UK, Canada, India and Egypt registers. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is ImmunityBio, Inc (13). The most-studied condition is Urothelial Carcinoma.
Where Anktiva is approved
All regulators →Of the three regulators tracked here, the first to approve Anktiva was the US, on 22 Apr 2024. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
NICE appraisals of Anktiva
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Anktiva. 1 is current.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation) NICE TA1163 | Terminated (no company submission) | 4 Jun 2026 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Anktiva
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- EUEuropean Union: AnktivaEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Anktiva
14 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Anktiva
23 conditionsAll 23 conditions
| Condition (as registered) | Trials |
|---|---|
| Urothelial Carcinoma | 2 |
| Long COVID | 2 |
| NSCLC Stage IV | 1 |
| Metastatic Urothelial Carcinoma | 1 |
| Locally Advanced Urothelial Carcinoma | 1 |
| Urothelial Cancer | 1 |
| Long COVID Syndrome | 1 |
| Long Covid 19 | 1 |
| Metastatic Solid Tumor | 1 |
| Pancreatic Cancer | 1 |
| Platinum-resistant Ovarian Cancer | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Small Cell Lung Cancer | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Bladder Cancer | 1 |
| Non-muscle Invasive Bladder Cancer | 1 |
| Glioblastoma | 1 |
| Advanced Lung Non-Small Cell Carcinoma | 1 |
| Recurrent Lung Non-Small Cell Carcinoma | 1 |
| Stage III Lung Cancer AJCC v8 | 1 |
| Stage IIIA Lung Cancer AJCC v8 | 1 |
| Non Hodgkin's Lymphoma Refractory/Relapsed | 1 |
| Non Muscle Invasive Bladder Cancer | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| ImmunityBio, Inc | 13 |
| SWOG Cancer Research Network | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 13 | 5 |
| Clinical trials in Mexico | 2 | 0 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in India | 1 | 0 |
| Clinical trials in Egypt | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Anktiva trials
How many clinical trials are testing Anktiva?
14 current trials in our USA, Mexico, UK, Canada, India and Egypt registers name Anktiva (also registered as N-803) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Anktiva trials recruiting patients?
Yes. 5 of the 14 trials are recruiting: 5 with sites in USA, 1 with sites in UK and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Anktiva clinical trials?
ImmunityBio, Inc (13) and SWOG Cancer Research Network (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Anktiva works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anktiva works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anktiva (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.